同日多家药企新药在华获批上市，自研罕见病创新药引人注目

动脉网2025-12-23

2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。其中，和誉医药研发、默克商业化的1类创新药盐酸匹米替尼胶囊（商品名“贝捷迈”）通过优先审评获批，用于治疗症状性腱鞘巨细胞瘤成年患者；葛兰素史克中国宣布新可来®（美泊利珠单抗注射液）获批用于未充分控制的以血嗜酸性粒细胞升高为特征的慢性阻塞性肺疾病成人患者维持治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593546606?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 09:44","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593546606","market":"us","top_or_hot":-1,"title":"同日多家药企新药在华获批上市，自研罕见病创新药引人注目","media":"动脉网","content":"<div>\n<p>2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。其中，和誉医药研发、默克商业化的1类创新药盐酸匹米替尼胶囊（商品名“贝捷迈”）通过优先审评获批，用于治疗症状性腱鞘巨细胞瘤成年患者；葛兰素史克中国宣布新可来®（美泊利珠单抗注射液）获批用于未充分控制的以血嗜酸性粒细胞升高为特征的慢性阻塞性肺疾病成人患者维持治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同日多家药企新药在华获批上市，自研罕见病创新药引人注目</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同日多家药企新药在华获批上市，自研罕见病创新药引人注目\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。其中，和誉医药研发、默克商业化的1类创新药盐酸匹米替尼胶囊（商品名“贝捷迈”）通过优先审评获批，用于治疗症状性腱鞘巨细胞瘤成年患者；葛兰素史克中国宣布新可来®（美泊利珠单抗注射液）获批用于未充分控制的以血嗜酸性粒细胞升高为特征的慢性阻塞性肺疾病成人患者维持治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b","article_id":"2593546606","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593546606","pubTimestamp":1766454240,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4599":"减肥药","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","GSK":"葛兰素史克","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","MRK":"默沙东","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓"},"translate_title":"On the same day, a number of new drugs from pharmaceutical companies were approved for marketing in China, and self-developed innovative drugs for rare diseases attracted attention","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.86,"MRK":1.84,"NVO":1.88},"content_text":"2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。其中，和誉医药研发、默克商业化的1类创新药盐酸匹米替尼胶囊（商品名“贝捷迈”）通过优先审评获批，用于治疗症状性腱鞘巨细胞瘤成年患者；葛兰素史克中国宣布新可来®（美泊利珠单抗注射液）获批用于未充分控制的以血嗜酸性粒细胞升高为特征的慢性阻塞性肺疾病成人患者维持治疗，该药此前已在中国获批用于其他多种病症治疗；福安药业子公司收到盐酸曲唑酮片药品注册证书，适用于抑郁症治疗；诺和诺德宣布减重版司美格鲁肽注射液心血管适应证上市申请在中国获批，适用于降低特定成人患者主要心血管不良事件风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593546606","isCrawlerRequest":true}